Report overview
SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.
This report aims to provide a comprehensive presentation of the global market for Systemic Lupus Erythematosus (SLE) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Systemic Lupus Erythematosus (SLE) Drugs. This report contains market size and forecasts of Systemic Lupus Erythematosus (SLE) Drugs in global, including the following market information:
Global Systemic Lupus Erythematosus (SLE) Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Systemic Lupus Erythematosus (SLE) Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Systemic Lupus Erythematosus (SLE) Drugs companies in 2022 (%)
The global Systemic Lupus Erythematosus (SLE) Drugs market was valued at US$ 168 million in 2022 and is projected to reach US$ 261.2 million by 2029, at a CAGR of 6.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing support for emerging research areas for new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment as well as consistent research and development processes for novel drug molecules are important drivers for global lupus erythematous market. Additionally, safety and quality of systemic lupus erythematous controlling therapy may possibly be a challenge for the growth of the global systemic lupus erythematous drugs market. Moreover, numerous public awareness programs targeted to increase awareness levels are also being accompanied. For instance, Lupus Foundation of America (LFA) has been implementing various projects to increase central support for SLE research and services to support people and families affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for new treatment options with better levels of efficacy and safety are obstructing the global systemic lupus erythematous drugs market.
We surveyed the Systemic Lupus Erythematosus (SLE) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Systemic Lupus Erythematosus (SLE) Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Systemic Lupus Erythematosus (SLE) Drugs Market Segment Percentages, by Type, 2022 (%)
Corticosteroids
Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Anti-Inflammatories
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Antimalarials
BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
Immunosuppressive Agents/Immune Modulators
Anticoagulants
Global Systemic Lupus Erythematosus (SLE) Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Systemic Lupus Erythematosus (SLE) Drugs Market Segment Percentages, by Application, 2022 (%)
Intravenous
Sub-Cutaneous
Oral
Topical
Global Systemic Lupus Erythematosus (SLE) Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Systemic Lupus Erythematosus (SLE) Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Systemic Lupus Erythematosus (SLE) Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Systemic Lupus Erythematosus (SLE) Drugs revenues share in global market, 2022 (%)
Key companies Systemic Lupus Erythematosus (SLE) Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Systemic Lupus Erythematosus (SLE) Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Anthera Pharmaceuticals
GSK
ImmuPharma
Johnson & Johnson
Outline of Major Chapters:
Chapter 1: Introduces the definition of Systemic Lupus Erythematosus (SLE) Drugs, market overview.
Chapter 2: Global Systemic Lupus Erythematosus (SLE) Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Systemic Lupus Erythematosus (SLE) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Systemic Lupus Erythematosus (SLE) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Systemic Lupus Erythematosus (SLE) Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
